Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the Investigator believes that they can and will comply with the requirements of the protocol.~* A male or female between, and including, 18 and 50 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject prior to any study procedure.~* Subjects must be HIV-positive and must have:~  * received Highly Active Antiretroviral therapy for a minimum of 12 consecutive months prior to screening~ * documented suppressed HIV-1 RNA levels following HAART-treatment.~ * a protocol defined CD4+ T cell count at screening~* If the subject is female, she must be of non-childbearing potential, or she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of vaccination.~* Clinically acceptable laboratory values prior to randomisation as determined by the Investigator.~* No evidence of TB disease with no pulmonary pathology as confirmed by chest X-ray.~* No history of extrapulmonary TB.~* No history of chemotherapy for TB.~Exclusion Criteria:~* Any change in antiretroviral drug regimen within 12 weeks prior to screening.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Administration of a registered live vaccine not foreseen by the study within 30 days preceding the first dose of study vaccine and administration of a registered inactivated vaccine within 14 days preceding the first dose of study vaccine.~* History of previous administration of experimental Mycobacterium tuberculosis vaccines.~* History of previous exposure to experimental products containing components of the experimental vaccine.~* Chronic administration of immunosuppressive or other immune-modifying drugs within six months prior to the first vaccine dose.~* Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period.~* Any condition or illness (acute, chronic or history) or medication, which in the opinion of the Investigator might interfere with the evaluation of the safety or immunogenicity of the vaccine.~* Planned participation or participation in another experimental protocol during the study period.~* A family history of congenital or hereditary immunodeficiency. •Any chronic drug therapy, other than HAART or prophylaxis for opportunistic HIV-related infections to be continued during the study period. Vitamins and/or dietary supplements, birth control pills, anti-histamines for seasonal allergies and SSRIs are allowed.~* Subjects taking any of the following medication: systemic steroids, interleukins, systemic interferons or systemic chemotherapy.~* History of allergic reactions or anaphylaxis to any vaccine.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of chronic alcohol consumption and/or drug abuse which in the Investigator's opinion would put the subject at risk.~* Pregnant female, lactating female or female planning to become pregnant or stop contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects receiving the candidate vaccine
- Group B (Type: PLACEBO_COMPARATOR): Subjects receiving the adjuvant
- Group C (Type: PLACEBO_COMPARATOR): Subjects receiving physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).